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Background: Fenofibrate offers a number of benefits on the cardiovascular system and it is plausible that its anti-
inflammatory, anti-oxidant and anti-fibrotic effects and enhancement of cardiac metabolic performances may
account for its direct cardioprotective effects.
In this study we aimed to investigate the effect of fenofibrate on endothelial function assesed by vascular studies
and levels of soluble E-selectin (sE-selectin) as well as the effect on plasma myeloperoxidase (MPO) in patients with
type 2 diabetes mellitus (T2DM) without previous use of lipid-lowering medication.
Methods: 27 patients (14 men and 13 women) with T2DM and good glycemic control (HbA1c: min 5.9%, max:
7.1%) treated with metformin monotherapy, without previous use of lipid-lowering medication were enrolled in this
study. Vascular studies included measures of brachial artery diameter before and after release of a suprasystolic
ischemia. FMD was calculated as the percent (%) change in arterial diameter following reactive hyperemia. Student’s
paired t test and Wilcoxon Signed Ranks Test were used to compare values before and after fenofibrate therapy.
Results: Fenofibrate therapy significantly increased post ischemia mean brachial artery diameter at 60 s (from 4.7
[4.4; 5.0] mm to 4.9 [4.6; 5.2] mm, p = 0.01) and at 90 s (from 4.7 [4.4; 5.0] mm to 4.9 [4.6; 5.1], p = 0.02). FMD
response to hyperaemia at 60 s increased with 4.5 ± 13.7% (median value pre- treatment: 22.2%, median value
post- treatment 25.0%, z = −2.9, p = 0.004). After 8 weeks of fenofibrate therapy, plasma MPO levels decreased to
49.5 [30.3; 71.5] ng/ml (% change from baseline = 4.6%, z = −2.2, p = 0.03) and mean plasma sE-selectin levels
decreased to 67.1 [54.4; 79.8] ng/ml, (% change from baseline = 2.6%, p = 0.03).
Conclusion: In patients with T2DM without previous treatment for dyslipidemia, short-term treatment with
fenofibrate improved vascular endothelial function as demonstrated by increased post ischemia mean brachial
artery diameter, increased FMD and decreased plasma sE-selectin and favorably affected plasma MPO levels.
Therefore, fenofibrate may be considered a protective cardiovascular drug in this group of patients.
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Type 2 diabetes mellitus (T2DM) is associated with a
high risk of cardiovascular (CV) events, irrespective of
the presence of other traditional risk factors [1]. Current
evidence suggests the central role of endothelium in all
phases of the atherosclerotic process [2]. Most CV risk
factors activate molecular pathways that result in in-
creased expression of cytokines and cellular adhesion
molecules involved in the adhesion and migration of
monocytes into the subendothelial space [2,3], leading to
the initiation, progression, and destabilization of the ath-
erosclerotic lesion. E-selectin is a molecule of endothelial
origin, which has been associated with carotid atheroscler-
osis and incident coronary heart disease [3,4]. Flow medi-
ated dilation (FMD) evaluates endothelial dependent
dilation in the brachial artery after occlusion, a measure of
endothelial function in humans [5,6].
Myeloperoxidase (MPO) is a predominantly leukocyte-
derived enzyme, involved in the initiation, destabilization
of atherosclerotic plaque and genesis of acute coronary
syndromes [7]. Plasma MPO levels have been positively
associated with coronary artery disease (CAD) and risk
of a subsequent cardiac event [8-11].
Therefore, drugs that have the potential to influence
both vascular function and MPO have become highly in-
teresting, especially if already used in the treatment of
other CV risk factors in persons with diabetes. Fenofi-
brate offers a number of benefits on the CV system
[12-14] and it is plausible that its anti-inflammatory,
anti-oxidant and anti-fibrotic effects and enhancement
of cardiac metabolic performances may account for its
direct cardioprotective effects [15-17]. Previous studies
showed that these effects could be mediated by decreased
plasma high sensitivity C-reactive protein, fibrinogen,
plasminogen activator inhibitor (PAI)-1 and decreased
monocyte cytokine release [15], suppression of thromb-
oxane A2 receptor, cytosolic calcium mobilization, and
cyclooxygenase (COX)-1 activity [16] and decrease in in-
ducible nitric oxide synthase, cyclooxygenase (COX)2 and
matrix metallopeptidase 9 (MMP-9) [17].
The main purpose of this study was to investigate the
role of fenofibrate on endothelial function, assessed by
vascular studies and soluble E-selectin (sE-selectin), and
on plasma MPO in patients with T2DM without previ-
ous use of lipid-lowering medication.
Methods
Study design and protocol
This was an interventional, open label study enrolling
patients with T2DM treated with metformin alone, and
without previous use of lipid-lowering medication. Par-
ticipants were recruited from a T2DM population in an
outpatient clinic from Romania. According to treatment
protocols in place in Romania, each patient with diabetestreated with non-insulinic drugs must attend a specialist
visit twice a year.
Participants were enrolled between August 1st and
September 15, 2012 and followed for 8 weeks.
Each participant attended 3 study visits: screening, visits
1 and 2 (8 weeks apart). Starting from visit 1 participants
fulfilling inclusion criteria and without any exclusion cri-
teria, received 160 mg fenofibrate/day for 8 weeks. The
pills were counted at the end of study; compliance was
considered satisfactory if >90% of them were taken.
Before and at the end of the study, data were collected
on medical history (visit 1), anthropometric variables,
blood pressure (BP), FMD of the brachial artery, as well
as adverse events (visit 2). Blood samples were collected
at screening, visit 1 and 2 in fasting conditions as de-
scribed below. At visit 1 each participant received in-
structions to maintain his/her usual nutritional habits
and not to modify any drug treatment throughout the
study.
The research was conducted in accordance with the
guidelines in The Declaration of Helsinki and Good Clin-
ical Practice. Study protocol was approved by the Iuliu
Hatieganu University of Medicine and Pharmacy Ethics
Committee. Written informed consent was obtained from
each participant prior to any study procedures.
Study objectives were to assess
1. The variation of brachial artery diameters and of FMD
response to hyperaemia, after 8 weeks of treatment
with fenofibrate compared to pre-treatment values
2. The variation of plasma MPO and soluble sE-selectin
after 8 weeks of treatment with fenofibrate as
compared with pre-treatment values.
Study population
We enrolled men and women ≥18 years of age, with
T2DM defined according to World Health Organization
criteria (WHO) [18], who were on stable doses of met-
formin for at least 3 months, with glycated haemoglobin
(HbA1c) <7.5% and without previous treatment with any
lipid-lowering drugs.
Exclusion criteria were: known type 1 and other spe-
cific types of diabetes (e.g. genetic defects of the β-cell,
genetic defects in insulin action, diseases of the exocrine
pancreas, endocrinopathies, drug- or chemical-induced
diabetes, infections, uncommon forms of immune-
mediated diabetes, other genetic syndromes associated
with diabetes) according to WHO classification of dia-
betes mellitus [18], treatment with other hypoglycaemic
drugs during the 3 months preceding the screening visit,
any acute cardiovascular event within last 3 months,
genetic conditions affecting lipids metabolism (e.g. famil-
ial hypercholesterolemia, lipoprotein lipase deficiency),
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kidney disease (glomerular filtration rate [eGFR] <50 ml/
min/1.73 m2, contraindicating treatment with fenofi-
brate), serum triglyceride level ≥400 mg/dl, hepatic en-
zymes >3 upper normal limits (UNL), history of alcohol
abuse, changes in antihypertensive therapy during the
last 3 months.
Data collection and laboratory tests
A complete medical history, including diabetes duration
and treatment, was obtained for each participant; height,
weight and waist circumference were determined by a
standardized protocol. Waist circumference was mea-
sured at half of the distance between the lower border of
the last rib and the upper border of the iliac crest at the
end of a normal expiration, using a non-stretchable tape
measure. Body mass index (BMI) was calculated as
weight (kg)/[height (m)]2. Blood pressure was measured
using a calibrated standard mercury sphygmomanom-
eter. All readings were taken after a 5-min rest, in the
sitting position.
Fasting blood samples were collected in the morning
after an 8 h overnight fasting period. Fasting plasma glu-
cose, HbA1c, total cholesterol, high-density lipoprotein
(HDL) cholesterol, triglycerides, creatinine, hepatic en-
zymes were determined by automated chemistry analyzer
Konelab 30, Thermo Fisher Scientific Inc, Finland. Low-
density lipoprotein (LDL) cholesterol was calculated using
Friedewald formula [19]. eGFR was estimated using online
available Modification of Diet in Renal Disease (MDRD)
calculator (http://www.nephron.com/MDRD_GFR.cgi). sE-
selectin and plasma MPO were measured in plasma
(EDTA) using commercially available enzyme-linked im-
munosorbent assay kits for quantitative detection (DRG
Diagnostics GmbH, Germany and DRG International, Inc,
USA) on an automated ELISA reader (Tecan).
Adverse events were recorded throughout of study.
Safety parameters included serum creatinine, eGFR, and
hepatic enzymes.
Vascular studies
Imaging studies of the right brachial artery were per-
formed in fasting condition before and after 8 weeks of
fenofibrate therapy with a high-resolution, ultrasound
imaging system (Aloka ProSound Alpha 10 Premier,
Aloca Co., Ltd.) using M-mode, and electrocardiogram-
triggered ultrasound images obtained with a 10 MHz
linear-array transducer. All vascular studies were per-
formed according to a protocol previously described by
Celermajer and co-workers [5], by measuring the arterial
response to reactive hyperemia. Studies were performed
at 20–24°C in a dark, quiet room. The study participant
rested for at least 10 min before the first scan and
remained in a recumbent position throughout theinvestigation. Scanning of the brachial artery was per-
formed 3–10 cm above the elbow, at baseline (before is-
chemia) and at 45, 60, 90, and 120 s after release of a
suprasystolic ischemia of the forearm with a pneumatic
cuff, inflated at 250 mmHg for 4 min. Images were taken
at the end of the diastole and digitalized. Four cardiac
cycles were analyzed at the end of the diastole, and ar-
terial diameter was automatically measured using special
software (E-tracking) and then averaged. FMD was cal-
culated as the percent (%) change in arterial diameter
following reactive hyperemia when compared to the
baseline diameter.
Statistical analysis
Statistical analysis was performed using SPSS-PC 15.0
(SPSS Inc., Chicago, IL, USA). Data were considered to
be normally distributed if the ratio of skewness to its
standard deviation did not exceed the value of 2. Data
were expressed as a mean [95% Confidence Interval] for
variables with normal distribution, median [1st quartile;
3rd quartile] for variables with abnormal distribution or
frequency for dichotomial variables. Student’s paired t test
(for variables with normal distribution) and Wilcoxon
Signed Ranks Test (for variables with deviations from nor-
mal distribution) were used to compare values before and
after fenofibrate therapy. Correlations were assessed with
Pearson’s and Spearman’s correlation coefficient analysis.




Twenty seven patients (14 men and 13 women) fulfilling
the inclusion criteria and without any exclusion criteria
were enrolled in this study. Two participants (one male
and one female) did not complete the study: one was ex-
cluded from the study due to poor compliance with
fenofibrate treatment and one dropped out soon after
fenofibrate treatment initiation for personal reasons and
refused to present for reevaluation. Mean duration of
diabetes was 3.8 years. All participants had good gly-
cemic control (HbA1c range: 5.9%-7.1%). Doses of met-
formin ranged from 850 to 3000 mg/day. 76.0% of study
participants had a history of hypertension and 20.0% had
cardiovascular diseases. Characteristics of study partici-
pants are presented in Table 1.
Compared with baseline, at visit 3 participants pre-
sented significantly lower levels of total cholesterol
(−24.3 mg/dl, p = 0.002), triglycerides levels (−54.9 mg/
dl, p < 0.001), systolic and diastolic blood pressure
(−6.8 mmHg, p = 0.04 and −3.8 mmHg, p = 0.02, respect-
ively). No statistically significant effect was observed on
HDL-cholesterol and on LDL-cholesterol (p > 0.05). In
addition, no change was observed in fasting plasma
Table 1 Characteristics of the 25 patients at baseline and at follow up (8 weeks of treatment)
Variables Visit 1 (Pre-treatment) Visit 2 (Post treatment) p
Age (years) 59.2 [55.2; 63.2] -
Male gender (%) 13.0 (52.0%) -
Current smoker 4.0 (16.0%) -
Hypertension 19.0 (76.0%) -
Cardiovascular disease 5.0 (20.0%) -
Ischemic heart disease 4.0 (16.0%) -
Ischemic stroke 1.0 (4%) -
Medication
ACEI 10.0 (40.0%) -
β-Adrenergic receptor blocker 8.0 (32.0%) -
Diuretics 8.0 (32.0%) -
Calcium channel blocker 7.0 (28.0%) -
Angiotensin receptor blocker 4.0 (16.0%) -
Aspirin 7.0 (28.0%) -
SBP (mmHg) 149.8 [143.5; 156.1] 142.7 [137.6; 147.8] 0.04
DBP (mmHg) 91.5 [87.4; 95.5] 87.5 [82.8; 92.2] 0.02
BMI (kg/m2) 28.7 [26.6; 34.2]a 28.7 [26.7; 34.0]a 0.79
Waist (cm) 108.5 [104.0; 113.0] 110.4 [105.5; 115.3] 0.06
FPG (mg/dl) 136.9 [129.0; 144.8] 137.6 [129.7; 145.5] 0.82
HbA1c (%) 6.5 [6.3; 6.8] 6.5 [6.3; 6.7] 0.53
Lipids
Total cholesterol (mg/dl) 182.0 [166.0; 220.0]a 168.0 [151.0; 192.5]a 0.01
HDL cholesterol (mg/dl) 45.0 [40.1; 50.0] 44.1 [37.7; 50.5] 0.88
LDL-cholesterol (mg/dl) 104.0 [93.0; 139.3]a 102.0 [89.1; 125.6]a 0.14
Triglycerides (mg/dl) 168.6 [140.2; 197.0] 114.1 [95.4; 132.8] <0.001
eGFR (ml/min/1.73 m2) 107.7 [93.4; 122.0] 96.8 [82.6; 111.1] 0.007
TGO (IU/L) 20.0 [15.5; 25.0]a 22.0 [18.0; 26.0]a 0.10
TGP (IU/L) 22.0 [17.0; 27.0]a 24.0 [20.0; 28.0]a 0.48
Data in table are presented as mean [95%CI] for continuous variables, median [1st quartile; 3rd quartile] for variables with abnormal distribution and number (%)
for categorical variables; a- abnormal distribution; BMI - body mass index; HbA1c – glycosilated hemoglobin; SBP –systolic blood pressure; DBP – diastolic blood
pressure; FPG – fasting plasma glucose; eGFR- estimated glomerular filtration rate.
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ment (Table 1, p >0.05).
FMD
The variation of brachial artery diameters before and
after treatment is shown in Figure 1. Mean basal brachial
artery diameter was similar at each ultrasound assessment,
with no significant difference between pre-treatment and
post-treatment diameter (p = 0.34). Post ischemia mean
brachial artery diameter at 60 s and 90 s increased signifi-
cantly after fenofibrate therapy: from 4.7 [4.4; 5.0] mm to
4.9 [4.6; 5.2] mm at 60 s, p = 0.01 and from 4.7 [4.4; 5.0]
mm to 4.9 [4.6; 5.1] at 90 s, p = 0.02). No significant differ-
ences between pre-treatment and post-treatment diameter
were observed at 45 s and 120 s (p = 0.18 and 0.67,
respectively).Additionally, compared with pre-treatment values, FMD
response to hyperaemia at 60 s increased with 4.5 ± 13.7%
(median value pre- treatment: 22.2%, median value post-
treatment 25.0%, z = −2.9, p = 0.004) (Figure 2).
No correlations were observed between changes in
FMD and changes in total cholesterol (Spearman correl-
ation coefficient ρ = −0.1, p = 0.50), triglycerides (ρ = −0.3,
p = 0.07) or changes in systolic BP (ρ = −0.2, p = 0.37) or
diastolic BP (ρ = −0.08, p = 0.72).
MPO and sE-selectin
At baseline, MPO values ranged from 16.5 to 236.5 ng/ml,
with a median level of 55.0 [38.5; 85.3] ng/ml and values
of sE- selectin ranged from 15.0 to 142.0 ng/ml, with a
mean level of 75.2 [59.9; 90.5] ng/ml. After 8 weeks of
fenofibrate therapy, plasma MPO levels decreased to 49.5
Figure 1 Effect of fenofibrate on brachial artery diameter in basal conditions and during hyperemia at 45, 60, 90 and 120 seconds.
*Statistically significant difference in mean brachial artery diameter pre- and post-treatment. Error bars represent 95% confidence intervals Basal,
before hyperemia; 45 s, hyperemia 45 s; 60 s, hyperemia 60 s; 90 s, hyperemia 90 s; 120 s, hyperemia 120 s.
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−2.2, p = 0.03) (Figure 3) and mean plasma sE-selectin
levels decreased to 67.1 [54.4; 79.8] ng/ml (% change from
baseline = 2.6%, p = 0.03) (Figure 4).
MPO and endothelial dysfunction
No correlation was observed between % change in MPO
levels and % change in FMD (Spearman correlation coef-
ficient ρ = 0.3, p = 0.18) or between % change in MPO
levels and % change in E selectin (Spearman correlation
coefficient ρ = −0.2, p = 0.29).
Safety parameters
No serious adverse effects were observed throughout the
study, and none of the patients withdrew due to adverse
effects. A statistically significant decrease of eGFR oc-
curred between baseline and final visit (107.7 [93.4; 122.0]
vs. 96.8 [82.6; 111.1] ml/min/1.73 m2, p = 0.007) (Table 1).
Discussions
In this study, we showed that fenofibrate improved
endothelial dysfunction in T2DM patients without previ-
ous use of lipid-lowering medication and that thisFigure 2 Effect of fenofibrate on percent flow-mediated dilation.
Bars represent median values; error bars represent quartile 1 and
quartile 3% FMD, percent flow-mediated dilation.improvement was not related to changes of the lipid
profile or blood pressure. We also showed that fenofi-
brate reduced plasma MPO concentrations.
Our results demonstrated that short term treatment
with fenofibrate significantly decreased total cholesterol
and triglycerides concentrations. Additionally, we
showed that it significantly improved post ischemia bra-
chial artery diameter and FMD, an effect which was in-
dependent of the reduction in plasma lipids and blood
pressure, decreased plasma MPO and sE-selectin levels
and BP values.
Effect of fenofibrate on lipid profile
Regarding the effect of fenofibrate on plasma triglycer-
ides and total cholesterol, our results are consistent with
those of large clinical trials, showing that fenofibrate
therapy in patients with dyslipidemia is associated with
significant reductions of triglycerides, total and LDL-
cholesterol levels, and increases HDL-cholesterol levels
[12,20-25]. We did not observe any improvement in
LDL and HDL- cholesterol levels. This may be explained
by the normal lipid levels observed in most of the partic-
ipants enrolled in our study.Figure 3 Myeloperoxidase levels (ng/ml) before and after
treatment with fenofibrate. Bars represent median values; error
bars represent quartile 1 and quartile 3 MPO, myeloperoxidase.
Figure 4 sE-selectin levels (ng/ml) before and after treatment
with fenofibrate. Error bars represent 95% confidence intervals.
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The results of our study showed a small but significant
reduction in both systolic and diastolic BP. In several
animal models it was shown that fenofibrate may have a
favorable effect on this parameter. Shatara et al. demon-
strated that fenofibrate reduced blood pressure in
stroke-prone spontaneously hypertensive rats and Dahl
salt-sensitive rats [26]. Also, fenofibrate prevented the
development of hypertension, myocardial inflammation
and fibrosis in Ang-II-infused rats [27]. However, no
data in humans have been published.Effect of fenofibrate on vasomotor function
(FMD and sE-selectin)
The results of our study revealed that fenofibrate ther-
apy significantly improved post ischemia brachial artery
diameter and %FMD. This finding is consistent with
other studies that have shown significantly improved
FMD response to hyperemia in patients with metabolic
syndrome or hypertriglyceridemia following 6–8 weeks
of fenofibrate administration [28-30]. A similar effect, par-
tially related to enhanced reduction in LDL-cholesterol
and apoB-100 concentrations, has been shown in T2DM
patients treated with statins [31]. It was also observed that
short-term treatment with fenofibrate improves vascular
endothelial function in healthy normolipidemic middle-
aged and older adults by reducing oxidative stress and in-
duces an increase in endothelial nitric oxide synthase [13].
A favorable impact of 8-week treatment with fenofi-
brate on FMD in T2DM patients with typical or mixed
dyslipidemia has recently been reported [32], and this ef-
fect was independent of reduction in lipid parameters.
These findings are concordant with our results, suggest-
ing that in patients with T2DM fenofibrate could have
positive effects on endothelial dysfunction beyond its
antihyperlipidemic action. It cannot be excluded that
more subtle changes such as LDL cholesterol particlesize could be, at least in part, responsible for improve-
ment in endothelial function with fenofibrate.
We cannot completely exclude that changes in systolic
and diastolic BP had an impact on FMD, despite lacking
correlations between the three parameters. The inter-
pretation of this possible relationship is limited by the
study design which was not placebo-controlled.
Regarding the improvement in sE-selectin levels seen in
our study, the results are discordant with those derived
from the Fenofibrate Intervention and Event Lowering in
Diabetes (FIELD) trial and other studies showing that both
long-term and short-term fenofibrate treatment have no
effect on this marker of arterial damage [33,34].
Observational studies have suggested that there is a
strategic accumulation of MPO at the interface between
endothelium and media. This observation led to the hy-
pothesis that MPO could affect vascular tone by deplet-
ing endothelium derived NO [35,36]. Subendothelial
accumulated MPO can act locally as an NO oxidase,
inhibiting NO function and causing endothelial dysfunc-
tion [37]. The recently published work of Rudolph et al.
demonstrated that MPO elicits profound effects on vas-
cular tone of conductance and resistance vessels both in
humans, and in animal models [38]. Their results
showed a significant inverse correlation between FMD
and MPO plasma levels prior to and following nicotine
application (r = −20.33, P = 0.03; r = −20.30, P = 0.04)
[38]. Another research conducted by Vita et al. sug-
gested that there was a strong, independent relation be-
tween serum MPO level and endothelial dysfunction, as
reflected by brachial artery flow–mediated dilation [39].
By contrast, we observed that there was no correlation
between % changes in MPO levels and % change in
FMD or % changes in E selectin, suggesting that changes
in FMD and E selectin were independent from changes
in MPO levels and could be directly attributed to fenofi-
brate therapy.
A possible explanation for the favorable effects of
fenofibrate on endothelial function in T2DM, independ-
ent of its antihiperlipidemic action, is that this drug has
direct anti-inflammatory and anti-oxidant effects on vas-
cular wall, a hypothesis that was partially confirmed in
healthy normolipidemic subjects [13] but not yet tested
in patients with diabetes.
Effect of fenofibrate on plasma myeloperoxidase
To our knowledge, no prior human study has examined
the effect of fenofibrate on plasma MPO concentration.
Given that MPO adversely influences LDL atherogenic
properties and HDL functionality, it may be hypothesized
that drugs reducing this enzyme level could have certain
benefits in reducing the risk for atherosclerotic events.
Experimental and clinical studies provide support for a
potential impact of statin therapy on tissue and plasma
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[40-43]. In clinical studies, statins reduced circulating
levels of MPO in patients with congestive heart failure
[40], acute coronary syndromes [41] and patients with dia-
betes on dialysis [42]. The study conducted by Ndrepepa
et al. demonstrated an association between therapy with
beta-blockers on admission and reduced circulating levels
of plasma MPO which was independent of cardiovascular
risk factors, clinical characteristics and concomitant ther-
apy in a consecutive series of patients with symptomatic
CAD [43].
If our results regarding the beneficial effect of fenofi-
brate on plasma MPO and on endothelial function will
be confirmed in larger populations of patients with
T2DM, this drug could become a valuable option for
reducing atherosclerotic process in this group of high car-
diovascular risk patients as part of an early and compre-
hensive preventive strategy.
Safety issues
Our results regarding the decline in renal function are
concordant with those in the FIELD and Action to Con-
trol Cardiovascular Risk in Diabetes (ACCORD) studies
showing that fenofibrate caused an acute, sustained
plasma creatinine increase [25,44]. In a recent FIELD
sub study, Davies et al. assessed fenofibrate’s renal effects
and found no evidence that the initial increase in plasma
creatinine levels represented true renal injury, a finding
that has important implications for clinical care [45].
Moreover, it seems that despite initial and reversible in-
crease in plasma creatinine levels, fenofibrate may delay
albuminuria and GFR impairment in T2DM patients [46].
Limitations of the study
The main limitations of the present study are the rela-
tively small number of patients included and the short
duration of the fenofibrate treatment.
Conclusions
In patients with T2DM without previous treatment for
dyslipidemia, short-term treatment with fenofibrate im-
proved vascular endothelial function as demonstrated by
increased post ischemia mean brachial artery diameter,
increased FMD and decreased plasma sE-selectin and fa-
vorably affected plasma MPO levels. Therefore, fenofi-
brate may be considered a protective cardiovascular
drug in this group of patients.
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